AU2001285349A1 - Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 - Google Patents

Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2

Info

Publication number
AU2001285349A1
AU2001285349A1 AU2001285349A AU8534901A AU2001285349A1 AU 2001285349 A1 AU2001285349 A1 AU 2001285349A1 AU 2001285349 A AU2001285349 A AU 2001285349A AU 8534901 A AU8534901 A AU 8534901A AU 2001285349 A1 AU2001285349 A1 AU 2001285349A1
Authority
AU
Australia
Prior art keywords
erk
extracellular
induction
receptor expression
ldl receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001285349A
Inventor
Kamal D. Mehta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas
Original Assignee
University of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Arkansas filed Critical University of Arkansas
Publication of AU2001285349A1 publication Critical patent/AU2001285349A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10Transferases (2.)
    • C12N9/12Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809Methods for determination or identification of nucleic acids involving differential detection
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00Screening for compounds of potential therapeutic value
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/04Endocrine or metabolic disorders
    • G01N2800/044Hyperlipemia or hypolipemia, e.g. dyslipidaemia, obesity
AU2001285349A 2000-08-30 2001-08-29 Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2 Abandoned AU2001285349A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22927100P 2000-08-30 2000-08-30
US60229271 2000-08-30
PCT/US2001/026982 WO2002018654A1 (en) 2000-08-30 2001-08-29 Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2

Publications (1)

Publication Number Publication Date
AU2001285349A1 true AU2001285349A1 (en) 2002-03-13

Family

ID=22860499

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001285349A Abandoned AU2001285349A1 (en) 2000-08-30 2001-08-29 Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2

Country Status (3)

Country Link
US (1) US6756410B2 (en)
AU (1) AU2001285349A1 (en)
WO (1) WO2002018654A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20070335A1 (en) * 2005-08-30 2007-04-21 Novartis Ag SUBSTITUTE BENZIMIDAZOLES AND METHODS FOR THEIR PREPARATION
ATE459338T1 (en) 2006-07-21 2010-03-15 Novartis Ag FORMULATIONS FOR BENZIMIDAZOLYLPYRIDYL ETHER
WO2010100127A1 (en) 2009-03-04 2010-09-10 Novartis Ag Disubstituted imidazole derivatives as modulators of raf kinase
JO3002B1 (en) 2009-08-28 2016-09-05 Irm Llc Compounds and compositions as protein kinase inhibitors
US8242260B2 (en) 2009-08-28 2012-08-14 Novartis Ag Compounds and compositions as protein kinase inhibitors
CN102770426B (en) 2010-02-05 2016-03-23 诺瓦提斯公司 As compound and the composition of kinases inhibitor
KR20140117684A (en) 2010-06-25 2014-10-07 노파르티스 아게 Heteroaryl compounds and compositions as protein kinase inhibitors
KR102006917B1 (en) * 2016-06-01 2019-08-02 부산대학교 산학협력단 Pharmaceutical composition comprising ribosome-binding agent for preventing or treating low density lipoprotein-related disease

Also Published As

Publication number Publication date
WO2002018654A1 (en) 2002-03-07
US20020082192A1 (en) 2002-06-27
US6756410B2 (en) 2004-06-29

Similar Documents

Publication Publication Date Title
AU7288100A (en) Regulation of secondary metabolite production
ZA200106683B (en) Method for the preparation of citalopram.
HK1054378A1 (en) Method for the preparation of citalopram.
ZA200309471B (en) Method for the preparation of escitalopram.
MXPA03004030A (en) Process for the preparation of latent antithrombin iii.
AU2002356533A1 (en) Methods using 1, 2-dithiol-3-thiones and their derivatives and metabolites for inhibiting angiogenesis
ZA200403432B (en) Method for the preparation of escitalopram.
IL161026A0 (en) Process for the preparation of citalopram
AU2001285349A1 (en) Induction of ldl receptor expression by extracellular-signal regulated kinase, erk-1/2
AU2001252191A1 (en) Uses of bombesin receptor 3
MXPA03001800A (en) Process for the preparation of substituted phenylacetonitriles.
AU2002247063A1 (en) Antisense modulation of casein kinase 2-beta expression
AU2002330042A1 (en) Process for the preparation of 1,5-diarylpyrazoles
AU2001272368A1 (en) Method for the preparation of citalopram
AU2002303529A1 (en) Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
IL162188A0 (en) Process for the preparation of Ä1,4,5Ü-oxadiazepine derivatives
AU2002222695A1 (en) Novel 4'-demethyl-4'-o-substituted-1-deoxypodophyllotoxin derivative and geometric isomer thereof, process for the preparation thereof and anti-cancer composition comprising the same
AU2002317420A1 (en) Process for the preparation of citalopram hydrobromide
EP1295864A4 (en) Process for preparation of 1,5-diaminonaphthalenes
MXPA03009210A (en) New process for the preparation of oxabispidines.
IL137364A (en) Process for the preparation of 6,6-dimethylhept-1-en-4-yn-3-ol
AU2002338732A1 (en) Extracellular regulated kinase 2 (erk2)
AU2000258438A1 (en) An improved process for the preparation of acylferrocenes
AU2000279379A1 (en) An improved process for the preparation of 10h-phenoxazine
HK1041606B (en) Process for the preparation of n,n'-carbonylbislactams